Rising to the challenges of rare disease treatment
Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

T-cell Image

Specialized BioTherapeutics Pipeline

Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.

PreclinicalPhase 1Phase 2Phase 3NDA ReviewMarket
HyBryte™ Cutaneous T-Cell Lymphoma (CTCL) Treatment
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review
Market
SGX942 for Oral Mucositis Treatment
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review
Market
SGX203 for Pediatric Crohn’s Disease
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review
Market
SGX302 Plaque Psoriasis Treatment for Mild to Moderate Psoriasis
Preclinical
Phase 1
Phase 2
Phase 3
NDA Review
Market

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.

Public Health Solutions Pipeline

Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.

Proof-of-ConceptINDPhase 1Phase 2/3BLA ReviewMarket
RiVax® to Prevent Ricin Poisoning
Proof-of-Concept
IND
Phase 1
Phase 2/3
BLA Review
Market
SGX943 for Bacterial Infection Treatment
Proof-of-Concept
IND
Phase 1
Phase 2/3
BLA Review
Market
ThermoVax® Thermostable Vaccines for Global Use
Proof-of-Concept
IND
Phase 1
Phase 2/3
BLA Review
Market

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.
Papers and chars with medical data

Corporate Presentation

January 8, 2024

Stay on top of the latest Soligenix news

Subscribe To Our Newsletter